indication

Asperger Syndrome

Competitive landscape

as of 2026-07-01
Competitive set
1
1 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
4 events
2018
2020
2022
2024
2026
2028
2030
2032
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 21 trial
OwnerSumitomo Pharmaceuticals America
Protection2031

Market size

prevalence as a range, not a number